Efimov G A, Raats J M H, Chirivi R G S, van Rosmalen J W G, Nedospasov S A
National Research Center for Hematology, Ministry of Healthcare of the Russian Federation, Moscow, 125167 Russia.
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
Mol Biol (Mosk). 2017 Nov-Dec;51(6):1062-1068. doi: 10.7868/S0026898417060167.
Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab.
肿瘤坏死因子（TNF）是一种促炎细胞因子，与多种自身免疫性疾病和炎症性疾病的发病机制有关。抗TNF治疗彻底改变了自身免疫性疾病的治疗模式，成为单克隆抗体临床应用最成功的范例之一。目前，全球数百万患者正在使用抗TNF治疗。目前，全人源抗TNF抗体阿达木单抗是全球最畅销的抗细胞因子药物。在此，我们讲述一个关于一种高效抗TNF单克隆抗体的故事，该抗体最初在20多年前被鉴定出来，并进一步发展为嵌合型和人源化版本。我们对该抗体与英夫利昔单抗和阿达木单抗进行了比较分析。
